158 related articles for article (PubMed ID: 9625535)
1. Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications.
Tagliaferri P; Guarrasi R; Caraglia M; Morelli D; Fabbrocini A; Correale P; Bianco AR
Cancer Immunol Immunother; 1998 May; 46(3):121-7. PubMed ID: 9625535
[No Abstract] [Full Text] [Related]
2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
3. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
4. An acidic microenvironment inhibits antitumoral non-major histocompatibility complex-restricted cytotoxicity: implications for cancer immunotherapy.
Fischer B; Müller B; Fisch P; Kreutz W
J Immunother; 2000; 23(2):196-207. PubMed ID: 10746546
[TBL] [Abstract][Full Text] [Related]
5. Analysis of effector mechanisms in cancer.
Lotzová E
Curr Opin Immunol; 1989 Jun; 1(5):904-9. PubMed ID: 2679738
[No Abstract] [Full Text] [Related]
6. An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.
Müller B; Fischer B; Kreutz W
Immunology; 2000 Mar; 99(3):375-84. PubMed ID: 10712667
[TBL] [Abstract][Full Text] [Related]
7. The cellular and molecular basis of natural antitumor immunity in renal cell carcinoma patients.
Schendel DJ; Falk CS; Frankenberger B; Noessner E; Schleypen J; Pohla H
Urologe A; 2004 Sep; 43 Suppl 3():S133-5. PubMed ID: 15179552
[No Abstract] [Full Text] [Related]
8. An analysis of the relationship between gamma delta T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity.
Mavaddat N; Robinson BW; Rose AH; Manning LS; Garlepp MJ
Immunol Cell Biol; 1993 Feb; 71 ( Pt 1)():27-37. PubMed ID: 8436409
[TBL] [Abstract][Full Text] [Related]
9. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.
Slovin SF; Maguire HC; Mastrangelo MJ
Cancer; 1990 Dec; 66(12):2541-6. PubMed ID: 2123415
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
11. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
Lotzová E
Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
[TBL] [Abstract][Full Text] [Related]
12. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
[No Abstract] [Full Text] [Related]
13. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
14. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
15. MHC gene control of the natural killer system at the level of the target and the host.
Kärre K
Semin Cancer Biol; 1991 Oct; 2(5):295-309. PubMed ID: 1773046
[TBL] [Abstract][Full Text] [Related]
16. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
[No Abstract] [Full Text] [Related]
17. Adoptive immunotherapy for cancer.
Rosenberg SA
Sci Am; 1990 May; 262(5):62-9. PubMed ID: 2333496
[No Abstract] [Full Text] [Related]
18. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy.
Schendel DJ; Oberneder R; Falk CS; Jantzer P; Kressenstein S; Maget B; Hofstetter A; Riethmüller G; Nössner E
J Mol Med (Berl); 1997 Jun; 75(6):400-13. PubMed ID: 9231880
[TBL] [Abstract][Full Text] [Related]
19. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
Karlhofer FM; Ribaudo RK; Yokoyama WM
Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
[TBL] [Abstract][Full Text] [Related]
20. Induction of nonspecific cell-mediated cytotoxicity: a multisignal event and its cellular regulation.
Atzpodien J; Bührer C; Gulati SC; Wisniewski D; Oz S; Kirchner H; Benter T; Poliwoda H; Welte K; Clarkson B
Haematol Blood Transfus; 1989; 32():273-80. PubMed ID: 2625252
[No Abstract] [Full Text] [Related]
[Next] [New Search]
